How will we decide which therapies to give patients with metastatic melanoma once the new immunotherapies are available?
There are a number of new targets, therapies and approaches in AML being investigated but which ones look most promising in this challenging landscape?
After a few setbacks in clinical development, some solid data is emerging with AbbVie/Genentech's ABT-199/GDC-0199 in CLL. Some more mature data at ASCO was very encouraging...
Diffuse large B cell lymphomas (DLBCL) are an aggressive subset of non-Hodgkins lymphomas that generally have a poor prognosis and a high unmet medical need. There is a raft of promising new therapies being evaluated for treatment.
Initial phase 2 data for Amgen's blinatumomab in B cell ALL looked encouraging 2 years ago but has it held up over time?
Several new agents in development emerged for the treatment of aggressive NHL (DLBCL and FL), including SGN-CD19A, polatuzumab vedotin and pinatuzumab vedotin.
A review of poster data at ASCO 2014 for new drugs from new cancer drugs from $CLDX, $OMED & NuCana BioMed.
Selection of some of the many posters that caught our attention. Companies whose products are mentioned include: $EXEL, $RHHBY, $XLRN, $MRK
After it's successful IPO, what are some of the challenges and opportunities facing Kite Pharma and their CAR-T cell immunotherapy?
AstraZeneca showed impressive data at ASCO 2014 for MEDI4736, a new anti PD-L1 immunotherapy.
There have been no new therapies in urothelial bladder cancer for 30 years - until now...
PD-1 antibodies nivolumab and pembrolizumab show considerable promise in metastatic melanoma. At ASCO 2014 we learnt more about how they compare against each other and their potential as a backbone for combinations.
What does the ASCO 2014 data show when you combine checkpoint inhibitors nivolumab and ipilimumab?
With the intense focus on immino-oncology, are targeted agents passe now?
A predictive biomarker for resistance to treatment by enzalutamide and abiraterone may lead to new prostate cancer drug development opportunities.
Clovis Oncology CO-1686 is in competition with AstraZeneca's AZD9291, but was it really a "loser" at ASCO 2014 as many think it was?
Final day at ASCO 2014 - what are the diehards listening to this morning?
Live blog with commentary on Day 4 of the ASCO 2014 annual meeting in Chicago.
Live blog with updates from Day 3 at ASCO 2014
Live Blog from Day 2 of ASCO 2014 in Chicago.
Coverage of day 1 at ASCO 2014 with commentary on some of the poster highlights.
Update on the top drugs in CLL including ibrutinib, obinutuzumab, idelalisib, ABT-199, GS-9973, ONO-4059, CTL019, TAK659, IPI-145, cerdulatinib and others.
Highlights in multiple myeloma at ASCO include drugs with a different mechanism of action eg panobinostat, daratumumab and elotuzumab, #ASCO14
How we could overcome resistance to BRAF inhibitors in colon cancer with a triple combination approach